Q2 2026 Rockwell Medical Inc Earnings Call Transcript
Key Points
- Rockwell Medical Inc (RMTI) reported an 11% year-over-year increase in net sales for Q2 2026, driven by new customer growth and increased purchase activity.
- Gross margin expanded to 18% in Q2 2026, up from 16% in the prior year period, reflecting improved operational efficiency and higher volumes.
- The company generated approximately $2.1 million in positive operating cash flow during the quarter, ending with a strong cash balance of $24.8 million.
- Rockwell Medical Inc (RMTI) successfully signed a new agreement with Heritage Dialysis and renewed its long-standing relationship with Aqua Dialysis, strengthening its recurring revenue base.
- The company is making significant progress in the Western United States, a key growth area, with new customers transitioning business and contributing to higher-margin liquid product sales.
- Management reiterated its full-year 2026 guidance, expecting net sales between $70 million and $75 million, gross margin between 18% and 22%, and positive operating cash flow.
- Rockwell Medical Inc (RMTI) still reported a net loss of $1.2 million for Q2 2026, although this was an improvement from the $1.5 million loss in the prior year period.
- Adjusted EBITDA remained negative at -$200,000 for the second quarter, consistent with the prior year period.
- The company's six-month net sales were flat year-over-year, with growth only visible when excluding the impact of higher purchasing volumes from DaVita in the prior year.
- The company incurred expenses related to the evaluation and development of a new medical device opportunity, which represents a new area of investment risk.
- Management acknowledged a 'meaningful disconnect' between the company's current market valuation and its operational progress, indicating the stock price may not reflect the business's performance.
- The company had to complete a reverse stock split to regain compliance with NASDAQ's minimum bid price requirement, which can be viewed negatively by some investors.
Good morning and welcome to Rockwell Medical's second quarter 2026 results conference call and webcast. Please note this event is being recorded. At this time, I would like to turn the conference call over to Heather Hunter, Chief Operating Officer at Rockwell Medical. Heather, please go ahead.
Good morning, everyone, and thank you for joining us for this update on Rockwell Medical.
Joining me on today's conference call are Dr. Mark Strobeck, Rockwell Medical's President and CEO, and Jesse Neri, Rockwell Medical's CFO. Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meeting of the federal securities laws. Including but not limited to the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC.
These statements are subject to risks and uncertainties that could cause actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
